DPA
ATRA icon

Delphi Private Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Delphi Private Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-340
Closed -$121K – 110
2016
Q4 		$121K Buy
+340
New +$144K 0.21% 24

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Delphi Private Advisors's ATRA Position: Q1 2017 in Review

Delphi Private Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2017, closing a stake of 340 shares — an estimated $121K sold.

Delphi Private Advisors first reported a position in ATRA in Q4 2016 and held it in 1 quarter. The position peaked at $121K in Q4 2016. 85 funds tracked by Wall St. Rank hold ATRA as of Q1 2017.

  • Delphi Private Advisors reported no remaining Atara Biotherapeutics position as of Q1 2017 after selling out during the quarter.
  • Delphi Private Advisors sold 340 Atara Biotherapeutics shares in Q1 2017, an estimated $121K.
  • Delphi Private Advisors first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 1 quarter.
  • Delphi Private Advisors's Atara Biotherapeutics position peaked at $121K in Q4 2016.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2017.

Based on Delphi Private Advisors's 13F filing for Q1 2017, filed 25 Apr 2017.